THE ROLE OF MOLECULAR MARKERS IN GASTRIC AND ESOPHAGEAL PATIENTS
Gastric cancer has the second rank in the structure of all deaths from cancer and both gastric and esophageal cancers are the cause of 1 100 000 patients' deaths worldwide every year. Identification of gastric cancer markers for a more accurate prognosis for the course of disease and choice of adequate therapy is still an open problem. The review discusses literature data on correlation of expression and amplification of ERCC-1, Her-2/neu and Ki-67 with clinical course of disease, tumor histological characteristics and sensitivity to chemotherapy in patients with gastric and esophageal cancers.